Skip to main content
Jennifer Brown, MD, Oncology, San Mateo, CA

JenniferABrownMD

Oncology San Mateo, CA

Physician

Dr. Brown is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Brown's full profile

Already have an account?

  • Office

    218 De Anza Blvd
    San Mateo, CA 94402
    Phone+1 650-341-9131
    Fax+1 650-341-9135

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1999 - 2002
  • Rush Medical College of Rush University Medical Center
    Rush Medical College of Rush University Medical CenterClass of 1999

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - 2025
  • ME State Medical License
    ME State Medical License 2022 - 2025
  • CA State Medical License
    CA State Medical License 2000 - 2024
  • IL State Medical License
    IL State Medical License 2002 - 2005
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Publications & Presentations

PubMed

Press Mentions

  • Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor Day
    Verastem Oncology Reports on Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Opportunity, Landscape and Advancements in Pre-Commercial Initiatives at Analyst and Investor DayMay 3rd, 2018
  • Efforts Continue to Optimize Ibrutinib in CLL
    Efforts Continue to Optimize Ibrutinib in CLLJune 2nd, 2016
  • Newer Agents, Combinations Being Studied for Targeted Therapies in CLL
    Newer Agents, Combinations Being Studied for Targeted Therapies in CLLMarch 20th, 2016
  • Join now to see all

Professional Memberships